Overview
-$1.7MNet income, fiscal 20262
Compare with Palisades Venture Inc., Corvex, Inc. or AUDDIA INC., or pick any stock.
- TickerAVAI on OTC1
- IndustryServices-Computer Processing & Data Preparation1
- HeadquartersLas Vegas, Nevada1
- Incorporated inNV3
- Business address5348 Vegas Drive, Las Vegas, Nv 891083
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
July 18, 2023, FINRA announced the Company’s Name Change and Symbol Change, which became effective on July 19, 2023 on the OTC Markets.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Cost of revenue100¢$276.3K
Out of $276.3K in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Amortization Expense | $26.1K | $74.3K |
| Consulting Services | $258.4K | $517.7K |
| General and Administrative Expenses | $792.3K | $762.5K |
| Marketing Expenses | $290.6K | $85.2K |
| Professional Fees | $97.9K | $77.4K |
| Rent Expenses | $857 | |
| Research and Development Expenses | $15.0K | |
| Website Expenses | $14.8K | |
| TOTAL OPERATING EXPENSES | $1.5M | $1.5M |
| Debt Forgiveness | $450.0K | |
| Discount on Convertible Note | -$104.4K | -$47.8K |
| Interest on Convertible Note | -$140.0K | -$11.5K |
| Interest on Loan from Related Parties | -$24.9K | |
| NET INCOME (LOSS) FROM OPERATIONS | -$1.7M | -$1.1M |
| NET INCOME (LOSS) | -$1.7M | -$1.1M |
| COMPREHENSIVE INCOME (LOSS) | -$1.7M | -$1.1M |
| NET LOSS PER SHARE: BASIC AND DILUTED | -$0.01 | -$0.01 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 138.0M shares | 128.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and Cash Equivalents | $23.1K | $81.1K | |
| Loan Receivable | $60.1K | ||
| Prepaid Expenses | $6.1K | $12.1K | |
| Total Current Assets | $89.3K | $93.1K | |
| Intangible Assets, Net (Note 6) | $105.5K | $131.6K | |
| Due from Subsidiaries | $377.8K | ||
| Total Other Assets | $483.4K | $131.6K | |
| TOTAL ASSETS | $572.7K | $224.7K | |
| Accounts Payable | $1.6M | $885.3K | |
| Convertible Notes Payable (Note 8) | $500.5K | $391.3K | |
| Loan Payable - Related Parties (Note 7) | $744.4K | $512.1K | |
| Loan Payable (Note 8) | $550.0K | ||
| Total Current Liabilities | $3.4M | $1.8M | |
| Total Liabilities | $3.4M | $1.8M | |
| Preferred stock, $0.001 par value, 20,000,000 shares authorized; 11,300,000 and 11,300,000 common shares issued and outstanding respectively (Note 9) | $11.3K | $11.3K | |
| Preferred stock Series A, $0.001 par value, 5,000 shares authorized; 3,050 and 3,050 shares issued and outstanding, respectively (Note 9) | $15.2K | $15.2K | |
| Common stock, $0.001 par value, 500,000,000 shares authorized; 153,211,252 and 137,363,513 common shares issued and outstanding respectively (Note 9) | $153.2K | $137.4K | |
| Additional Paid in Capital | $2.9M | $2.4M | |
| Accumulated Deficit | -$5.9M | -$4.1M | |
| Total Stockholders Deficit | -$2.8M | -$1.6M | -$1.5M |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $572.7K | $224.7K | |
| Preferred Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 20.0M shares | 20.0M shares | |
| Preferred Stock, Shares Issued | 11.3M shares | 11.3M shares | |
| Preferred Stock, Shares Outstanding | 11.3M shares | 11.3M shares | |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 500.0M shares | 500.0M shares | |
| Common Stock, Shares, Issued | 153.2M shares | 137.4M shares | |
| Common Stock, Shares, Outstanding | 153.2M shares | 137.4M shares |
| Period ending | 2026-03-31 | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Cash and Cash Equivalents | $23.1K | $81.1K | |
| Loan Receivable | $60.1K | ||
| Prepaid Expenses | $6.1K | $12.1K | |
| Total Current Assets | $89.3K | $93.1K | |
| Intangible Assets, Net (Note 6) | $105.5K | $131.6K | |
| Due from Subsidiaries | $377.8K | ||
| Total Other Assets | $483.4K | $131.6K | |
| TOTAL ASSETS | $572.7K | $224.7K | |
| Accounts Payable | $1.6M | $885.3K | |
| Convertible Notes Payable (Note 8) | $500.5K | $391.3K | |
| Loan Payable - Related Parties (Note 7) | $744.4K | $512.1K | |
| Loan Payable (Note 8) | $550.0K | ||
| Total Current Liabilities | $3.4M | $1.8M | |
| Total Liabilities | $3.4M | $1.8M | |
| Preferred stock, $0.001 par value, 20,000,000 shares authorized; 11,300,000 and 11,300,000 common shares issued and outstanding respectively (Note 9) | $11.3K | $11.3K | |
| Preferred stock Series A, $0.001 par value, 5,000 shares authorized; 3,050 and 3,050 shares issued and outstanding, respectively (Note 9) | $15.2K | $15.2K | |
| Common stock, $0.001 par value, 500,000,000 shares authorized; 153,211,252 and 137,363,513 common shares issued and outstanding respectively (Note 9) | $153.2K | $137.4K | |
| Additional Paid in Capital | $2.9M | $2.4M | |
| Accumulated Deficit | -$5.9M | -$4.1M | |
| Total Stockholders Deficit | -$2.8M | -$1.6M | -$1.5M |
| TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $572.7K | $224.7K | |
| Preferred Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 20.0M shares | 20.0M shares | |
| Preferred Stock, Shares Issued | 11.3M shares | 11.3M shares | |
| Preferred Stock, Shares Outstanding | 11.3M shares | 11.3M shares | |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 500.0M shares | 500.0M shares | |
| Common Stock, Shares, Issued | 153.2M shares | 137.4M shares | |
| Common Stock, Shares, Outstanding | 153.2M shares | 137.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Net Loss | -$1.7M | -$1.1M |
| Amortization | $26.1K | $74.3K |
| Prepaid Expenses | $6.0K | $103.7K |
| Accounts Payable | $707.6K | -$196.5K |
| Net cash used in Operating Activities | -$1.0M | -$1.2M |
| Additional Paid in Capital | $482.4K | $1.0M |
| Capital Stock | $15.8K | $20.2K |
| Convertible Notes Payable | $109.3K | $190.3K |
| Due from Subsidiaries | -$377.8K | |
| Loan from Related Parties | $232.3K | $105.3K |
| Loan Payable | $550.0K | -$99.0K |
| Loan Receivable | -$60.1K | |
| Preferred Stock | $1.3K | |
| Net cash provided by Financing Activities | $951.9K | $1.2M |
| Net cash increase (decrease) for period | -$57.9K | $80.8K |
No quarter-by-quarter statement was filed.
What it owns
What AVAI BIO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $23.1K2 Mar 31, 2026 | $81.1K2 Mar 31, 2025 | −71.4% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $131.6K14 Mar 31, 2025 | $205.9K14 Mar 31, 2024 | −36.1% |
| Finite-lived intangibles, net | $105.5K2 Mar 31, 2026 | $131.6K14 Mar 31, 2025 | −19.8% |
Properties, in its own words
We do not own any real estate or other properties. The Company rents a virtual office at 5348 Vegas Drive, Las Vegas, NV 89108. The company’s registered office is located at Sv. Stepono g. 27D-2, LT-01315 Vilnius, Lithuania.
Item 2 of the 10-K filed Jul 14, 2026.4
Former names
Timeline
- May 8, 20268-K Entered a material agreement15
- Feb 9, 20268-K Other events16
- Nov 4, 20258-K Entered a material agreement17
- Sep 18, 20258-K Entered a material agreement18
- Sep 17, 20258-K Other events19
- May 13, 20258-K Ended a material agreement20
- Feb 27, 20258-K Entered a material agreement21
- Nov 12, 20248-K Entered a material agreement22
- Oct 31, 20248-K Entered a material agreement23
- Sep 10, 20248-K Ended a material agreement; Executive or director change24
- Jul 22, 20248-K Entered a material agreement25
- Jul 15, 20248-K Entered a material agreement; Executive or director change26
Filings
78 filings to the SEC since October 2021: 9 annual reports, 18 quarterly reports, 34 major events, 17 other. The latest 20:
- Aug 13, 202610-Q REPORT 10-Q EDGAR
- Jul 14, 202610-K REPORT 10-K EDGAR
- Jun 30, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
- May 8, 20268-K EDGAR
- Feb 12, 202610-Q REPORT 10-Q EDGAR
- Feb 9, 20268-K EDGAR
- Nov 14, 202510-Q REPORT 10-Q EDGAR
- Nov 4, 20258-K EDGAR
- Sep 18, 20258-K EDGAR
- Sep 17, 20258-K EDGAR
- Aug 12, 202510-Q REPORT 10-Q EDGAR
- Jul 8, 202510-K REPORT 10-K EDGAR
- Jun 30, 2025NT 10-K NOTIFICATION OF LATE FILING EDGAR
- May 13, 20258-K EDGAR
- May 13, 2025RW WITHDRAWAL REQUEST EDGAR
- Apr 11, 2025S-1/A EDGAR
- Feb 28, 2025S-1 EDGAR
- Feb 27, 20258-K EDGAR
- Feb 19, 202510-K/A EDGAR
- Feb 19, 2025UPLOAD EDGAR
The 78 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How AVAI BIO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAVAI BIO, INC.1
- CIK0001740797
- Employer ID (EIN)38-40530644
- Filer statusNon-accelerated filer not a shell company4
- Incorporated inNevada4
- Fiscal year endsMarch 311
- Industry code (SIC)7374 Services-Computer Processing & Data Preparation1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address5348 Vegas Drive, Las Vegas, NV 891081
- Phone866-533-00651
- Shares outstanding153,916,565 as of Aug 13, 202612
- Public float$36.8M as of Mar 31, 20264
- AuditorDylan Floyd Accounting & Consulting, Newhall, California PCAOB ID 62354
- On EDGAR sinceJun 5, 20181
- Filings117 in all: 8-K (40), 10-Q (25), 10-K (8), NT 10-Q (8), 10-K/A (6), NT 10-K (6), 10-Q/A (5), UPLOAD (5)1
All 16 form types
8-K/A (3), S-1/A (3), CORRESP (2), S-1 (2), DEF 14C (1), DEFA14C (1), EFFECT (1), RW (1)
- Latest filingsAnnual report (10-K) Jul 14, 2026
Quarterly report (10-Q) Aug 13, 2026
Latest 8-K (8-K) May 8, 2026
Risk factors and legal proceedings
The risks AVAI BIO, INC. names in Item 1A of its 10-K filed Jul 14, 2026: 9 risks under these headings, as written.4
- Additional Risks Related to Our Common Stock
- Because we are quoted on the OTC QB marketplace instead of a national securities exchange, our investors may experience significant volatility in the market price of our stock and have difficulty selling their shares.
- Our stock price and trading volume may be volatile, which could result in substantial losses for our stockholders.
- We have not paid dividends in the past and have no immediate plans to pay cash dividends.
- Shares eligible for future sale may adversely affect the market for our Common Stock.
- You may experience future dilution as a result of future equity offerings.
- Our charter documents and Nevada law may inhibit a takeover that stockholders consider favorable.
- There are limitations on director/officer liability.
- Penny stock regulations may impose certain restrictions on marketability of our securities.
- FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock.
Legal proceedings
From time to time, the Company may be involved in various litigation matters, which arise in the ordinary course of business. There is currently no litigation that management believes will have a material impact on the financial position of the Company.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAVAI BIO, INC. filings on SEC EDGAR
- 2SEC EDGARAVAI BIO, INC. 10-K for fiscal 2026
- 3SEC EDGARAVAI BIO, INC. filings on SEC EDGAR
- 4
- 5SEC EDGARAVAI BIO, INC. 10-K for fiscal 2023
- 6SEC EDGARAVAI BIO, INC. 10-K for fiscal 2019
- 7SEC EDGARAVAI BIO, INC. 10-K for fiscal 2020
- 8SEC EDGARAVAI BIO, INC. 10-K for fiscal 2021
- 9SEC EDGARAVAI BIO, INC. 10-K for fiscal 2022
- 10SEC EDGARAVAI BIO, INC. 10-Q for fiscal 2025
- 11SEC EDGARAVAI BIO, INC. 10-Q for fiscal 2025
- 12SEC EDGARAVAI BIO, INC. 10-Q for fiscal 2026
- 13SEC EDGARAVAI BIO, INC. 10-K for fiscal 2019
- 14SEC EDGARAVAI BIO, INC. 10-K for fiscal 2025
- 15SEC EDGAREntered a material agreement
- 16SEC EDGAROther events
- 17SEC EDGAREntered a material agreement
- 18SEC EDGAREntered a material agreement
- 19SEC EDGAROther events
- 20SEC EDGAREnded a material agreement
- 21SEC EDGAREntered a material agreement
- 22SEC EDGAREntered a material agreement
- 23SEC EDGAREntered a material agreement
- 24
- 25SEC EDGAREntered a material agreement
- 26